GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (OTCPK:RDPTF) » Definitions » ROA %

Radiopharm Theranostics (Radiopharm Theranostics) ROA % : -71.53% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Radiopharm Theranostics ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Radiopharm Theranostics's annualized Net Income for the quarter that ended in Dec. 2023 was $-33.14 Mil. Radiopharm Theranostics's average Total Assets over the quarter that ended in Dec. 2023 was $46.33 Mil. Therefore, Radiopharm Theranostics's annualized ROA % for the quarter that ended in Dec. 2023 was -71.53%.

The historical rank and industry rank for Radiopharm Theranostics's ROA % or its related term are showing as below:

RDPTF' s ROA % Range Over the Past 10 Years
Min: -62.89   Med: -40.06   Max: -36.39
Current: -62.89

During the past 2 years, Radiopharm Theranostics's highest ROA % was -36.39%. The lowest was -62.89%. And the median was -40.06%.

RDPTF's ROA % is ranked worse than
69.63% of 1551 companies
in the Biotechnology industry
Industry Median: -34.84 vs RDPTF: -62.89

Radiopharm Theranostics ROA % Historical Data

The historical data trend for Radiopharm Theranostics's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics ROA % Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23
ROA %
-36.39 -42.66

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
ROA % -38.20 -29.42 -29.21 -54.98 -71.53

Competitive Comparison of Radiopharm Theranostics's ROA %

For the Biotechnology subindustry, Radiopharm Theranostics's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Radiopharm Theranostics's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's ROA % distribution charts can be found below:

* The bar in red indicates where Radiopharm Theranostics's ROA % falls into.



Radiopharm Theranostics ROA % Calculation

Radiopharm Theranostics's annualized ROA % for the fiscal year that ended in Jun. 2023 is calculated as:

ROA %=Net Income (A: Jun. 2023 )/( (Total Assets (A: Jun. 2022 )+Total Assets (A: Jun. 2023 ))/ count )
=-23.229/( (58.595+50.302)/ 2 )
=-23.229/54.4485
=-42.66 %

Radiopharm Theranostics's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-33.144/( (50.302+42.365)/ 2 )
=-33.144/46.3335
=-71.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


Radiopharm Theranostics  (OTCPK:RDPTF) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-33.144/46.3335
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-33.144 / 0)*(0 / 46.3335)
=Net Margin %*Asset Turnover
=N/A %*0
=-71.53 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Radiopharm Theranostics ROA % Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Radiopharm Theranostics (Radiopharm Theranostics) Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.

Radiopharm Theranostics (Radiopharm Theranostics) Headlines

From GuruFocus

PIVALATE ACHIEVES POSITIVE PHASE 2 DATA IN BRAIN METS TRIAL

By PRNewswire PRNewswire 10-19-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 07-10-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 06-10-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 06-30-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 06-20-2022